Search
Chlorphenoxamine
go.drugbank.com/drugs/DB09007ApprovedWithdrawnIt is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
Categories: Antihistamines, Anesthetics, Etc.Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigational[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Benzphetamine
go.drugbank.com/drugs/DB00865ApprovedIllicitIt is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Chlormadinone acetate
go.drugbank.com/drugs/DB15903ApprovedWithdrawnChlormadinone acetate is a progesterone derivative first synthesized in 1961. In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens. However, the use of these drugs ...
Mixtures: LUTORAL-E, BELARA film-coated tablet 0.03mg/2mgTeriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigational[A251395] It is made up of the first amino(N)-terminal 34 amino acids of the human PTH.
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnIt is used in the management of myasthenia gravis.
Calcium glycerophosphate
go.drugbank.com/drugs/DB11264ApprovedIt is also present in dental or oral hygiene products due to its cariostatic effects. … It is suggested that calcium glycerophosphate promotes plaque-pH buffering, elevation of plaque [DB01373] and phosphate levels and direct interaction with dental mineral [A27153].
Succinic acid
go.drugbank.com/drugs/DB00139ApprovedInvestigationalNutraceutical(Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) … It is also used in foods as a sequestrant, buffer, and a neutralizing agent.
Demecarium
go.drugbank.com/drugs/DB00944ApprovedIt is a cholinesterase inhibitor or an anticholinesterase. … Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264768] Acoramidis has been in development since at least 2013. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.